Are Mobotinib and Moboxetinib the same?

Mobocertinib and mobocertinib are different names for the same drug. They both refer to an oral tyrosine kinase inhibitor developed by Takeda Pharmaceuticals. The English name is Mobocertinib. This drug is mainly used to treat adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations.

Mobotinib, also known as mobosetinib, is a targeted drug developed by Takeda Pharmaceuticals. It is specifically targeted at NSCLC patients with EGFR exon 20 insertion mutations. This type of mutation is rare in lung cancer and difficult to treat. The development of mobotinib provides new treatment options for these patients.

Mobotinib, as a third-generation EGFR inhibitor, can interfere with the EGFR signaling pathway, thereby inhibiting the growth and division of cancer cells. Clinical trial results show that the drug can significantly extend patients' progression-free survival and overall survival. For example, in one study, the median progression-free survival of patients treated with mobotinib was improved to 7.3 months, and the median overall survival was extended to 20.2 months, which brought significant survival benefits to patients with EGFR exon 20 insertion mutations.

Mobotinib is an oral drug that adult patients need to take once daily at a dose of 160 mg. It is recommended to take it on an empty stomach or 2 hours after a meal to ensure the best absorption and effect of the drug. Of course, the specific medication regimen needs to be determined based on the patient's specific situation and the guidance of the doctor.

Although mobotinib is excellent in treating NSCLC with EGFR exon 20 insertion mutations, it may also cause some adverse reactions, such as diarrhea, rash, nausea, etc. Therefore, it is necessary to pay close attention to the patient's response during use and adjust the treatment plan in a timely manner according to the situation.